Skip to main content
BiogenPatent grant

Biogen was granted a patent for anti-transferrin receptor antibodies.

Source: Autobound Signal API · 74 signals tracked for Biogen · updated

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.

What happened

In November 2026 Biogen patented antibody compositions and genetic tools intended for therapeutic development and laboratory production.

Source

patents.google.comNov 17, 2026

US patent US12799197

Anti-transferrin receptor antibodies and uses thereof

Abstract

The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

patents.google.com/patent/US12799197Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
4
Patent number
US12799197
Assignee
Biogen MA Inc.

The full record

From the Signal API record

People

  • Isin Dalkilic-LiddleInventor
  • Benjamin A. SmithInventor
  • Karl J.M. HanfInventor
  • Fang QianInventor
  • R. Blake PepinskyInventor
  • Thomas O. CameronInventor

Details

Primary CPC class
C07K 16/28
USPTO assignee
Biogen MA Inc.
What the invention does
Antibodies designed to bind the transferrin receptor, along with the DNA, delivery vectors, and engineered cells used to produce and apply them.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Bioengineering

Technologies named

  • therapeutic antibodies
  • transferrin receptor targeting
  • biologic production

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/3a03d888-4f4d-58f4-b015-74303ef21851 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "3a03d888-4f4d-58f4-b015-74303ef21851",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:07:49+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 16/28"
      },
      {
        "code": "C12N 15/113"
      },
      {
        "code": "C07K 2317/565"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Bioengineering"
    ],
    "detail": "In November 2026 Biogen patented antibody compositions and genetic tools intended for therapeutic development and laboratory production.",
    "summary": "Biogen was granted a patent for anti-transferrin receptor antibodies.",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "Isin Dalkilic-Liddle",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/isin-dalkilic-liddle-9a272615"
      },
      {
        "name": "Benjamin A. Smith",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Karl J.M. Hanf",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Fang Qian",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "R. Blake Pepinsky",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/robert-blake-pepinsky-4b7642358"
      },
      {
        "name": "Thomas O. Cameron",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12799197",
    "cpc_primary": {
      "code": "C07K 16/28"
    },
    "patent_title": "Anti-transferrin receptor antibodies and uses thereof",
    "patent_number": "US12799197",
    "uspto_assignee": "Biogen MA Inc.",
    "patent_abstract": "The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.",
    "precision_class": "structural",
    "invention_explanation": "Antibodies designed to bind the transferrin receptor, along with the DNA, delivery vectors, and engineered cells used to produce and apply them.",
    "technologies_mentioned": [
      "therapeutic antibodies",
      "transferrin receptor targeting",
      "biologic production"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.